Roche Holding AG said one of the company’s experimental drugs helped women with a certain breast cancer mutation live longer without the disease progressing, according to Bloomberg.
Patients who took the oral drug inavolisib in combination with two other drugs fared significantly better in an early-stage study, Roche said Tuesday.
The drug combination could provide a more effective first treatment option for women with mutations called PIK3CA, which are linked to tumor growth, disease progression and resistance to treatment.
Global survival data is still immature at this point, Roche said, but scientists have noticed a positive trend.
The Swiss drugmaker is testing “inavolisib” in three late-stage breast cancer trials. If the drug does well and is approved by regulators, the company’s annual revenue could reach $532 million by 2028, according to Bloomberg estimates.
Roche shares were up less than 1 percent in Zurich trading, one of the worst performers among companies with the same operating goals.
The Swiss drugmaker, which has been asked to beef up its pipeline of new drugs, agreed on Monday to pay up to $3.1 billion for Carmot Therapeutics Inc., a developer of a new type of weight-loss treatment that has triggered a so-called “gold rush” in the pharmaceutical industry.
For other news, analyses, articles and business information in real time, follow Ziarul Financiar on WhatsApp Channels
2023-12-05 11:38:19
#pharmaceutical #industry #takes #step #fight #cancer #Swiss #drugmaker #Roche #product #called #inavolisib #generated #promising #results #among #breast #cancer #patients
